

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

vanke

CHINA VANKE CO., LTD.*

萬科企業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2202)

**THE INDICATIVE ANNOUNCEMENT REGARDING ADJUSTMENT TO H SHAREHOLDERS'
COMPLIANCE WITH EPIDEMIC PREVENTION ARRANGEMENTS TO
ATTEND THE 2021 ANNUAL GENERAL MEETING AND
THE FIRST H SHAREHOLDERS CLASS MEETING OF 2022**

References are made to the notice, the circular and the respective forms of proxy of annual general meeting (the “**Form of Proxy for the AGM**”) and Class meeting (the “**Form of Proxy for H Shareholders Class Meeting**”) of China Vanke Co., Ltd.* (the “**Company**”) dated 7 June 2022 in relation to the 2021 annual general meeting (the “**AGM**”) and the first H shareholders class meeting of 2022 (the “**Class Meeting**”, collectively with the “**AGM**”, the “**Meetings**”) (the abovementioned documents collectively referred to as the “**Series Announcements of the Meetings**”), and the announcement of the Company dated 21 June 2022 in relation to epidemic prevention arrangements of the Meetings. Unless the context otherwise requires, the terms used in this announcement shall have the same meanings as defined in the Series Announcements of the Meetings.

In view of latest epidemic prevention and control requirements from the location of the venue of the Meetings, **the effective timing of negative nucleic acid test report which enable the enter of the venue of the Meetings has been adjusted to 24 hours instead of 48 hours as previously announced.** Accordingly, the Company have made amendments to relevant information in epidemic prevention arrangements of the Meetings, which could be viewed in details in the remaining part of this announcement..

Other contents in the Series Announcements of the Meetings remain unchanged. The Company hereby remind matters regarding the recommendations to H Shareholders and their proxies who attend the Meetings and the epidemic prevention arrangements to be complied with by them again:

I. ACTIONS ADVISED BY THE COMPANY TO BE TAKEN BY H SHAREHOLDERS OR THEIR PROXIES

1. H Shareholders are recommended to attend the Meetings by proxy

In view of the possibility that the epidemic prevention and control requirements from the location of venue of the Meetings may be further tightened, the Company recommends H Shareholders to fill in and submit the Form of Proxy for the AGM and Form of Proxy for H shareholders Class Meeting (the “**Proxy Forms**”), appointing the chairman of the Meetings or other persons as proxies to attend the Meetings and exercise voting rights as instructed in the Proxy Forms.

2. Call the Company in advance

In order to safeguard the smooth participation of H Shareholders or their proxies at the Meetings, H Shareholders or their proxies who wish to attend the Meetings in person are strongly advised to call the Company (see below for specific contact numbers) at least 24 hours prior to the convening of the Meetings to confirm that they have complied with the following epidemic prevention arrangements and to register their contact information, but this recommendation will not affect the rights of the H Shareholders or their proxies to attend and vote at the Meetings in person.

II. EPIDEMIC PREVENTION ARRANGEMENTS TO BE COMPLIED WITH BY H SHAREHOLDERS OR THEIR PROXIES WHO WISH TO ATTEND THE ON-SITE MEETINGS

1. Strictly comply with the epidemic prevention and control requirements at the venue of the Meetings

The Company will take measures for prevention and control of the epidemic, such as registration for the Meetings, monitoring body temperature, and checking health code, telecommunication data based travel itinerary card and negative nucleic acid test report within **24 hours** prior to the convening of the Meetings, for Shareholders or proxies attending the Meetings on site, by complying with the requirements from the location of venue of the Meetings.

2. Circumstances under which H Shareholders cannot enter the venue of the Meetings

Any H Shareholder or his/her proxy will not be able to enter the venue of the Meetings under any of the following circumstances (including but not limited to):

- 1) he/she fails to provide a negative nucleic acid test report within 24 hours prior to the convening of the Meetings;**
- 2) his/her health code is in yellow or red colour;
- 3) his/her telecommunication data based travel itinerary card shows that the city or cities that he/she has arrived or passed through within 14 days prior to the convening of the Meetings with an “*” symbol;
- 4) he/she exhibits symptoms such as fever and cough;
- 5) he/she does not wear masks as required;
- 6) he/she fails to comply with other rules and requirements in relation to epidemic prevention and control at the venue of the Meetings.

III. CONTACT

For any inquiries regarding attending the Meetings, please contact before 27 June 2022 using the following ways:

Telephone: +86(755)2560 6666 transfer to Board Office

Fax: +86(755)2553 1696 (please indicate “transfer to Board Office” on the fax)

Email: IR@vanke.com

By order of the Board
China Vanke Co., Ltd.*
Zhu Xu
Company Secretary

Shenzhen, the PRC, 26 June 2022

As at the date of this announcement, the Board comprises Mr. YU Liang, Mr. ZHU Jiusheng and Mr. WANG Haiwu as executive directors; Mr. XIN Jie, Mr. HU Guobin, Mr. HUANG Liping and Mr. LEI Jiangsong as non-executive directors; and Mr. KANG Dian, Ms. LIU Shuwei, Mr. NG Kar Ling, Johnny and Mr. ZHANG Yichen as independent non-executive directors.

** For identification purpose only*